Morepen Laboratories, a mid-size pharma company, is all set to sell anti-asthmatic drug Montelukast in European and North American markets. The company eyes Rs. 100 crore global turnover in 2016-17 from this product.

Sushil Suri, Chairman and Managing Director, Morepen Lab said, “We are tying up in European and North American markets for supplies to ANDA (abbreviated new drug application) holders for the sale of Montelukast Sodium. The bulk drug has contributed Rs. 48 crore to the company’s total income in the nine-month period.”